Over a Decade of Innovation

We are pioneering a new era of medicines
Transforming the lives of patients living with serious diseases

Across a number of disease areas

Approved
Therapy

Clinical
Programs

Preclinical
Programs

First-ever approved crispr-based therapy

CASGEVY™ (Exagamglogene Autotemcel), a CRISPR/Cas9 Gene-Edited Therapy Arising Out of Our Collaboration with Vertex Pharmaceuticals Incorporated, Is Approved in Some Countries for Certain Eligible Patients with Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia.

Rapidly translating a revolutionary technology into therapies

Innovation that matters

Rapidly translating a revolutionary technology into therapies

Learn more about gene editing

Learn more about CRISPR-X

Learn more about our programs

We have established a diverse portfolio across a broad range of disease areas including hemoglobinopathies, oncology, diabetes and cardiovascular disease.

View Pipeline

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.

Continue

Over a Decade of Innovation

Across a number of disease areas

First-ever approved crispr-based therapy

Committed to patients

Innovation that matters

Learn more about our programs

Hemoglobinopathies

Immuno-Oncology

Autoimmune

In Vivo

Regenerative Medicine

CRISPR Therapeutics Corporate Presentation

You are now leaving the CRISPR Therapeutics website.